Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis

Abstract

It has been demonstrated that pitavastatin can significantly reduce low-density lipoprotein (LDL) cholesterol (LDL-C), but its impact on lipoprotein subfractions and oxidized low-density lipoprotein (oxLDL) has not been determined. The aim of the present study was to investigate the potential effects of pitavastatin on subfractions of LDL and high-density lipoprotein (HDL) as well as oxLDL in untreated patients with coronary atherosclerosis (AS). Thirty-six subjects were enrolled in this study. Of them, 18 patients with AS were administered pitavastatin 2 mg/day for 8 weeks and 18 healthy subjects without therapy served as controls. The plasma lipid profile, lipoprotein subfractions and circulating oxLDL were determined at baseline and 8 weeks respectively. The results showed that pitavastatin treatment indeed not only decreased LDL-C, total cholesterol (TC), triglycerides (TG) and apolipoprotein B (ApoB) levels, and increased HDL cholesterol (HDL-C), but also reduced the cholesterol concentration of all of the LDL subfractions and the percentage of intermediate and small LDL subfractions. Meanwhile, pitavastatin could decrease plasma oxLDL levels. Furthermore, a more close correlation was found between oxLDL and LDL-C as well as LDL subfractions after pitavastatin treatment. We concluded that a moderate dose of pitavastatin therapy not only decreases LDL-C and oxLDL concentrations but also improves LDL subfractions in patients with AS.

Keywords

pitavastatin / atherosclerosis / lipoprotein subfraction / low-density lipoprotein

References

[1] MuddJO, BorlaugBA, JohnstonPV, et al.. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol, 2007, 50(18): 1735-1741

[2] ReithC, ArmitageJ. Management of residual risk after statin therapy. Atherosclerosis, 2016, 245: 161-170

[3] XuRX, ZhangY, YeP, et al.. Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease. Heart Lung Circ, 2015, 24(12): 1203-1210

[4] QiY, FanJ, LiuJ, et al.. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol, 2015, 65(4): 355-363

[5] ZhuCG, ZhangY, XuRX, et al.. Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. J Clin Lipidol, 2015, 9(6): 794-800

[6] VorosS, JoshiP, QianZ, et al.. Apoprotein B, small-dense LDL and impaired HDL remodeling is associated with larger plaque burden and more noncalcified plaque as assessed by coronary CT angiography and intravascular ultrasound with radiofrequency backscatter: results from the ATLANTA I study. J Am Heart Assoc, 2013, 2(6): e000344

[7] JoksićJ, SopićM, Spasojević-KalimanovskaV, et al.. Higher circulating resistin protein and PBMCs resistin mRNA levels are associated with increased prevalence of small dense LDL particles in coronary artery disease patients. Clin Exp Pharmacol Physiol, 2016, 43(1): 22-28

[8] HuangYQ, CaiAP, ChenJY, et al.. The relationship of plasma mir-29a and oxidized low density lipoprotein with atherosclerosis. Cell Physiol Biochem, 2016, 40(6): 1521-1528

[9] WangA, YangY, SuZ, et al.. Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes. Stroke, 2017, 48(1): 91-97

[10] ZhangL, JiaYH, ZhaoXS, et al.. Trichosanatine alleviates oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the lox-1/p38 mapk pathway. Am J Transl Res, 2016, 8(12): 5455-5464

[11] BarriosV, EscobarC. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. Future Cardiol, 2016, 12(4): 449-466

[12] JeongHS, HongSJ, SonS, et al.. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol, 2019, 18(1): 162-170

[13] Vallejo-VazAJ, Kondapally SeshasaiSR, KurogiK, MichishitaI, et al.. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015, 241(2): 409-418

[14] ChristogiannisLG, KostapanosMS, TellisCC, et al.. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens, 2013, 27(1): 44-50

[15] GoliaschG, OravecS, BlessbergerH, et al.. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (</= 40 years of age). Eur J Clin Invest, 2012, 42(6): 631-636

[16] ElH K, van der SteegWA, StroesES, et al.. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007, 49(5): 547-553

[17] CromwellWC, OtvosJD, KeyesMJ, et al.. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study-Implications for LDL Management. J Clin Lipidol, 2007, 1(6): 583-592

[18] Toft-PetersenAP, TilstedHH, AaroeJ, et al.. Small dense LDL particles-a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. Lipids Health Dis, 2011, 10: 21-27

[19] XuRX, GuoYL, LiXL, et al.. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol, 2014, 41(7): 475-481

[20] SakuK, ZhangB, NodaK, et al.. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J, 2011, 75(6): 1493-1505

[21] TokunoA, HiranoT, HayashiT, et al.. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb, 2007, 14(3): 128-132

[22] SoneH, TakahashiA, ShimanoH, et al.. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci, 2002, 71(20): 2403-2412

[23] BarylskiM, TothPP, NikolicD, et al.. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab, 2014, 28(3): 453-461

[24] KypreosKE, GkizasS, RallidisLS, et al.. HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol, 2013, 85(11): 1575-1578

[25] SalonenJT, SalonenR, SeppanenK, et al.. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation, 1991, 84(1): 129-139

[26] KawanoM, NagasakaS, YagyuH, et al.. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb, 2008, 15(1): 41-46

[27] KakudaH, MatobaM, NakatohH, et al.. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scand J Clin Lab Invest, 2014, 74(4): 285-295

[28] FrostegardJ, ZhangY, SunJ, et al.. Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect. J Am Heart Assoc, 2016, 5(9): e003976

[29] HeL, XuR, WangJ, et al.. Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke. BMC Neurol, 2019, 19(1): 240-247

[30] TaguchiA, HayashiS. Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes. Nihon Rinsho, 2011, 69(1): 100-104